Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M166,603Revenue $M42,237Net Margin (%)27.0Altman Z-Score3.3
Enterprise Value $M181,388EPS $4.1Operating Margin %12.5Piotroski F-Score4
P/E(ttm)15.4Beneish M-Score-2.9Pre-tax Margin (%)40.0Higher ROA y-yY
Price/Book3.510-y EBITDA Growth Rate %5.4Quick Ratio1.3Cash flow > EarningsN
Price/Sales4.25-y EBITDA Growth Rate %4.0Current Ratio1.6Lower Leverage y-yN
Price/Free Cash Flow31.6y-y EBITDA Growth Rate %75.5ROA % (ttm)10.9Higher Current Ratio y-yN
Dividend Yield %3.0PEG3.9ROE % (ttm)23.3Less Shares Outstanding y-yY
Payout Ratio %46.0Shares Outstanding M2,825ROIC % (ttm)6.5Gross Margin Increase y-yN

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKVanguard Health Care Fund 2015-03-31 Add0.53%$56.06 - $63.03
($59.34)
$ 58.97-1%Add 12.04%40,096,948
MRKDodge & Cox 2015-03-31 Reduce-0.44%$56.06 - $63.03
($59.34)
$ 58.97-1%Reduce 24.30%25,448,977
MRKKahn Brothers 2015-03-31 Reduce-0.22%$56.06 - $63.03
($59.34)
$ 58.97-1%Reduce 2.18%1,029,815
MRKJoel Greenblatt 2015-03-31 Reduce-0.17%$56.06 - $63.03
($59.34)
$ 58.97-1%Reduce 35.28%676,758
MRKJames Barrow 2015-03-31 Add0.13%$56.06 - $63.03
($59.34)
$ 58.97-1%Add 7.03%24,464,116
MRKCharles Brandes 2015-03-31 Reduce-0.07%$56.06 - $63.03
($59.34)
$ 58.97-1%Reduce 3.69%2,221,791
MRKNWQ Managers 2015-03-31 Reduce-0.01%$56.06 - $63.03
($59.34)
$ 58.97-1%Reduce 9.00%76,286
MRKMario Gabelli 2015-03-31 Add0.01%$56.06 - $63.03
($59.34)
$ 58.97-1%Add 11.45%160,943
MRKKen Fisher 2015-03-31 Add$56.06 - $63.03
($59.34)
$ 58.97-1%Add 0.59%6,679,499
MRKKahn Brothers 2014-12-31 Reduce-0.54%$53.43 - $61.88
($58.42)
$ 58.971%Reduce 5.08%1,052,807
MRKVanguard Health Care Fund 2014-12-31 Add0.32%$53.43 - $61.88
($58.42)
$ 58.971%Add 7.08%35,788,048
MRKJoel Greenblatt 2014-12-31 Add0.23%$53.43 - $61.88
($58.42)
$ 58.971%Add 94.88%1,045,652
MRKFirst Eagle Investment 2014-12-31 Reduce-0.16%$53.43 - $61.88
($58.42)
$ 58.971%Reduce 99.16%9,050
MRKJoel Greenblatt 2014-09-30 Add0.24%$55.64 - $61.18
($58.89)
$ 58.970%Add 323.00%536,550
MRKFirst Eagle Investment 2014-09-30 Reduce-0.1%$55.64 - $61.18
($58.89)
$ 58.970%Reduce 38.25%1,083,826
MRKKahn Brothers 2014-09-30 Reduce-0.09%$55.64 - $61.18
($58.85)
$ 58.970%Reduce 0.97%1,109,189
MRKCharles Brandes 2014-09-30 Reduce-0.08%$55.64 - $61.18
($58.85)
$ 58.970%Reduce 4.69%2,320,288
MRKVanguard Health Care Fund 2014-09-30 Reduce-0.07%$55.64 - $61.18
($58.85)
$ 58.970%Reduce 1.38%33,420,748
MRKRobert Bruce 2014-09-30 Add0.06%$55.64 - $61.18
($58.85)
$ 58.970%Add 1.34%265,000
MRKDodge & Cox 2014-09-30 Reduce-0.05%$55.64 - $61.18
($58.85)
$ 58.970%Reduce 2.51%35,057,668
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Schechter Adam HEVP & Pres-Global Human Health 2015-05-11Sell10,634$60.44-2.43view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2015-05-08Sell38,368$60.99-3.31view
Kuhlik Bruce NExe V-P & Gen Counsel 2015-05-04Sell56,064$60.2-2.04view
Holston Michael JEVP, Legal 2015-04-29Sell95,624$59.84-1.45view
Kuhlik Bruce NExe V-P & Gen Counsel 2015-04-29Sell156,902$59.82-1.42view
FRAZIER KENNETH CChairman, President & CEO 2015-02-18Sell5,164$58.670.51view
Deese Willie AExe V-P & Pres. MMD 2015-02-11Sell135,864$58.560.7view
WENDELL PETER CDirector 2015-02-09Sell5,000$58.760.36view
Schechter Adam HEVP & Pres-Global Human Health 2015-01-15Sell74,200$62.48-5.62view
FRAZIER KENNETH CChairman, President & CEO 2015-01-09Sell8,840$62.47-5.6view

Press Releases about MRK :

    Quarterly/Annual Reports about MRK:

      News about MRK:

      Articles On GuruFocus.com
      Abbvie Inc. Dividend Stock Analysis May 26 2015 
      Endo International Acquires Par Pharmaceuticals For $8 Billion May 21 2015 
      Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
      Vanguard Adds to Four of Its Largest Stakes May 04 2015 
      Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
      Robert Bruce's Top Growth Stocks Apr 13 2015 
      Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Johnson & Johnson Unfazed By $25 Million Fine Mar 13 2015 
      Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 

      More From Other Websites
      Merck's (MRK) Keytruda a Step Closer to European Approval - Analyst Blog May 26 2015
      Merck Announces Third-Quarter 2015 Dividend May 26 2015
      Merck Announces Third-Quarter 2015 Dividend May 26 2015
      6:36 am Merck confirms a positive opinion from the CHMP for Simponi, to treat adult patients with... May 26 2015
      SIMPONI® (golimumab) Gains Positive Opinion from Committee for Medicinal Products for Human Use... May 26 2015
      Pharma Trumps All Healthcare Sectors In Executive Compensation May 26 2015
      Merck Serono supports 7th International Thyroid Awareness Week to Unmask Hypothyroidism May 26 2015
      Merck Serono Supports 7th International Thyroid Awareness Week to Unmask Hypothyroidism May 26 2015
      UPDATE 1-U.S. bird flu causes egg shortage, emergency measures May 23 2015
      Germany's Merck expects drug division to drive growth-Euro am Sonntag May 23 2015
      Germany's Merck expects drug division to drive growth-Euro am Sonntag May 23 2015
      U.S. bird flu causes egg shortage, emergency measures May 22 2015
      Expert Explains How To Play Merck In 2 Charts May 22 2015
      Merck KGaA Making Over Ambitious Growth Plans For Future? May 22 2015
      Merck Serono Announces CHMP Positive Opinion to Extend Kuvan Use to Children with PKU Below 4 Years... May 22 2015
      Merck follows Bristol with EU green light for immune cancer drug May 22 2015
      MSD Receives Positive CHMP Opinion for Pembrolizumab for the Treatment of Advanced Melanoma May 22 2015
      Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced... May 22 2015
      U.S. bird flu causing egg squeeze, emergency measures May 22 2015
      Merck Leads European Research Consortium on Printed Electronics May 22 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      FEEDBACK